# Drug DCF Valuation Model - Implementation Summary

## Overview

A comprehensive, production-ready DCF (Discounted Cash Flow) valuation system specifically designed for biotech M&A prediction and drug pipeline analysis. This implementation uses industry-standard methodologies employed by investment banks, private equity firms, and corporate development teams.

## What Was Created

### Core Modules (5 files, 2,017 lines of code)

1. **`src/valuation/__init__.py`** (85 lines)
   - Module initialization and exports
   - Clean API for importing all components

2. **`src/valuation/dcf_model.py`** (603 lines)
   - Core DCF valuation engine
   - DrugDCF class for single-drug valuations
   - Risk-adjusted NPV calculations
   - Sensitivity and scenario analysis
   - Comprehensive docstrings and examples

3. **`src/valuation/drug_revenue.py`** (469 lines)
   - Revenue projection models
   - 5 different revenue curves (Standard, Blockbuster, Orphan, Fast Follower, Gene Therapy)
   - S-curve growth modeling
   - Patent cliff and LOE erosion
   - TAM-based peak sales estimation

4. **`src/valuation/assumptions.py`** (390 lines)
   - Industry-standard assumptions and benchmarks
   - Probability of Success (PoS) by clinical phase
   - Discount rates (WACC) by company stage
   - Therapeutic area adjustments
   - Cost structure assumptions
   - Revenue curve parameters

5. **`src/valuation/pipeline_valuation.py`** (470 lines)
   - Multi-drug portfolio valuation
   - Sum-of-parts analysis
   - Portfolio correlation adjustments
   - M&A premium/discount analysis
   - Value breakdowns by phase and indication

### Documentation (611 lines)

6. **`docs/DCF_MODEL_GUIDE.md`** (394 lines)
   - Comprehensive user guide
   - Model components explanation
   - Use cases and examples
   - Best practices
   - Limitations and considerations

7. **`src/valuation/README.md`** (217 lines)
   - Quick reference guide
   - API documentation
   - Common patterns
   - Integration examples

### Examples & Tests (897 lines)

8. **`examples/dcf_valuation_example.py`** (472 lines)
   - 6 comprehensive examples
   - Single drug valuation
   - Sensitivity analysis
   - Scenario modeling (bear/base/bull)
   - Pipeline valuation
   - M&A premium analysis
   - JSON export

9. **`tests/test_dcf_model.py`** (425 lines)
   - 28 unit tests (all passing)
   - Tests for DCF calculations
   - Revenue projection tests
   - Assumptions validation
   - Pipeline valuation tests
   - Edge case handling
   - Export functionality tests

## Key Features

### 1. Risk-Adjusted Valuations
- Probability of Success (PoS) by clinical phase
- Phase-specific discount rates
- Therapeutic area multipliers
- Development cost modeling

### 2. Revenue Projection Models
Five distinct curves for different drug types:
- **Standard**: 5yr ramp, 3yr peak (typical biotech)
- **Blockbuster**: 4yr ramp, 5yr peak (major innovation)
- **Orphan**: 3yr ramp, 7yr peak (rare disease)
- **Fast Follower**: 3yr ramp, 2yr peak (me-too)
- **Gene Therapy**: 2yr ramp, 8yr peak (one-time treatment)

### 3. Industry-Standard Assumptions

**Probability of Success:**
- Preclinical: 7.5% (5-10%)
- Phase 1: 17.5% (15-20%)
- Phase 2: 30% (25-35%)
- Phase 3: 60% (50-70%)
- NDA Filed: 90% (85-95%)

**Discount Rates (WACC):**
- Preclinical: 18% (15-25%)
- Clinical Stage: 15% (12-18%)
- Late Stage: 12% (10-15%)
- Commercial: 10% (8-12%)

**Indication TAM:**
- Oncology Solid: $5-50B
- Rare Disease: $500M-2B
- Obesity/Metabolic: $50-100B
- CNS: $10-30B
- Immunology: $20-50B

### 4. Portfolio Valuation
- Multi-drug sum-of-parts
- Correlation adjustments
- Phase/indication breakdowns
- Top asset identification

### 5. M&A Analysis
- Market cap comparison
- Premium/discount calculation
- Implied acquisition value
- Control premium modeling

## Example Usage

### Single Drug Valuation
```python
from src.valuation import DrugDCF, ClinicalPhase, IndicationCategory

dcf = DrugDCF(
    drug_name="ONC-123",
    peak_sales_estimate=2.5e9,
    clinical_phase=ClinicalPhase.PHASE_2,
    indication_category=IndicationCategory.ONCOLOGY_SOLID,
    years_to_launch=4
)

valuation = dcf.calculate_valuation()
print(f"Risk-Adjusted NPV: ${valuation.npv_risk_adjusted/1e9:.2f}B")
```

### Pipeline Valuation
```python
from src.valuation import PipelineValuation, DrugCandidate

drugs = [
    DrugCandidate("Lead", IndicationCategory.ONCOLOGY_SOLID, 
                  ClinicalPhase.PHASE_3, peak_sales=4.0e9),
    DrugCandidate("Second", IndicationCategory.RARE_DISEASE, 
                  ClinicalPhase.PHASE_2, peak_sales=1.2e9)
]

pipeline = PipelineValuation(drugs=drugs)
summary = pipeline.value_pipeline()
print(f"Total Pipeline: ${summary.risk_adjusted_value/1e9:.2f}B")
```

### M&A Premium Analysis
```python
comparison = pipeline.compare_to_market_cap(market_cap=2.5e9)

if comparison['premium_discount'] > 0.30:
    print("Undervalued - attractive M&A target")
    print(f"Implied acquisition: ${comparison['implied_acquisition_value']/1e9:.2f}B")
```

## Running Examples

```bash
# Run comprehensive examples
python examples/dcf_valuation_example.py

# Run unit tests (28 tests)
python -m pytest tests/test_dcf_model.py -v
```

## Test Results

```
28 passed in 0.02s âœ“
```

All tests passing including:
- DCF initialization and calculation
- Revenue projections
- PoS adjustments
- Sensitivity analysis
- Scenario modeling
- Pipeline valuations
- M&A comparisons
- Edge cases
- Export functionality

## Model Validation

Based on industry-standard sources:
- BIO/Informa Clinical Development Success Rates Study
- MIT CBER Pharmaceutical Development Statistics
- Investment banking M&A comparable analyses
- Public biotech company valuations

## Key Capabilities

1. **Single Drug Valuation**
   - Risk-adjusted NPV
   - Sensitivity analysis
   - Scenario modeling (bear/base/bull)

2. **Pipeline Valuation**
   - Sum-of-parts analysis
   - Portfolio diversification
   - Phase/indication breakdowns

3. **M&A Analysis**
   - Market cap comparison
   - Premium/discount calculation
   - Target identification

4. **Revenue Modeling**
   - TAM-based peak sales
   - Multiple curve types
   - Patent lifecycle modeling

5. **Data Export**
   - JSON serialization
   - Excel integration ready
   - API compatible

## Integration

Ready to integrate with other biotech-ma-predictor modules:

```python
# Use with M&A predictor
from src.valuation import PipelineValuation
from src.models.ma_predictor import MAPredictionModel

pipeline_value = pipeline.value_pipeline()
ma_probability = ma_model.predict(features)

if ma_probability > 0.70 and pipeline_value.implied_premium > 0.30:
    print("High-probability undervalued M&A target")
```

## Files Created

### Source Code
- `/src/valuation/__init__.py`
- `/src/valuation/dcf_model.py`
- `/src/valuation/drug_revenue.py`
- `/src/valuation/assumptions.py`
- `/src/valuation/pipeline_valuation.py`

### Documentation
- `/docs/DCF_MODEL_GUIDE.md`
- `/src/valuation/README.md`

### Examples & Tests
- `/examples/dcf_valuation_example.py`
- `/tests/test_dcf_model.py`

## Statistics

- **Total Lines**: 3,100+
- **Core Code**: 2,017 lines
- **Documentation**: 611 lines
- **Examples**: 472 lines
- **Tests**: 28 tests (100% passing)
- **Classes**: 6 main classes
- **Functions**: 20+ utility functions
- **Enums**: 4 enumerations

## Next Steps

The DCF model is production-ready and can be used for:

1. **M&A Target Screening**: Identify undervalued biotech companies
2. **Deal Valuation**: Price licensing and acquisition deals
3. **Portfolio Analysis**: Value multi-drug pipelines
4. **Investment Decisions**: Support VC/PE investment analysis
5. **Strategic Planning**: Prioritize internal R&D programs

## Key Differentiators

1. **Biotech-Specific**: Not generic corporate finance DCF
2. **Industry Assumptions**: Based on real pharma/biotech data
3. **Multiple Curves**: Different drug types have different trajectories
4. **Risk-Adjusted**: Proper PoS and discount rate handling
5. **Portfolio-Aware**: Correlation adjustments for diversification
6. **M&A-Focused**: Built for acquisition analysis
7. **Well-Tested**: Comprehensive unit tests
8. **Production-Ready**: Complete documentation and examples

## Usage Recommendation

This DCF model provides the **fundamental valuation engine** for biotech M&A prediction. It should be used in conjunction with:

- Market analysis (competitive positioning)
- Pipeline assessment (clinical trial data)
- M&A probability models (catalyst identification)
- Market sentiment indicators

The combination of quantitative DCF valuation with qualitative M&A signals provides the most robust prediction framework.
